ScholarIQanswers from OpenAlex

Tolerance, variability, and pharmacokinetics of bevacizumab biosimilars in Chinese healthy male subjects

PaperCitations, authors & open-access status

Tolerance, variability, and pharmacokinetics of bevacizumab biosimilars in Chinese healthy male subjects is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Tolerance, variability, and pharmacokinetics of bevacizumab biosimilars in Chinese healthy male subjects have?

ScholarIQcitation count

Tolerance, variability, and pharmacokinetics of bevacizumab biosimilars in Chinese healthy male subjects has 20 citations in the OpenAlex counts ScholarIQ stores.

When was Tolerance, variability, and pharmacokinetics of bevacizumab biosimilars in Chinese healthy male subjects published?

ScholarIQyear

Tolerance, variability, and pharmacokinetics of bevacizumab biosimilars in Chinese healthy male subjects has 2018 year in the ScholarIQ index.

What is the open-access status of Tolerance, variability, and pharmacokinetics of bevacizumab biosimilars in Chinese healthy male subjects?

ScholarIQoa status

Tolerance, variability, and pharmacokinetics of bevacizumab biosimilars in Chinese healthy male subjects has closed oa status in the ScholarIQ index.

What is the DOI of Tolerance, variability, and pharmacokinetics of bevacizumab biosimilars in Chinese healthy male subjects?

ScholarIQdoi

The DOI for Tolerance, variability, and pharmacokinetics of bevacizumab biosimilars in Chinese healthy male subjects is on the source record.

What is the PMID of Tolerance, variability, and pharmacokinetics of bevacizumab biosimilars in Chinese healthy male subjects?

ScholarIQpmid

The PMID for Tolerance, variability, and pharmacokinetics of bevacizumab biosimilars in Chinese healthy male subjects is on the source record.

What is the OpenAlex record for Tolerance, variability, and pharmacokinetics of bevacizumab biosimilars in Chinese healthy male subjects?

ScholarIQopenalex

The OpenAlex for Tolerance, variability, and pharmacokinetics of bevacizumab biosimilars in Chinese healthy male subjects is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial